
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TMEM165 CRISPR/Cas9 KO Plasmid (h) | sc-412628 | 20 µg | $397.00 | |||
TMEM165 HDR Plasmid (h) | sc-412628-HDR | 20 µg | $445.00 |
TMEM165 encodes a multi-pass Golgi membrane protein implicated in maintaining Golgi ion homeostasis and supporting proper protein glycosylation. Disruption of TMEM165 perturbs Golgi function and glycosyltransferase activity, leading to altered N-glycan processing and broader effects on secretory pathway trafficking. TMEM165 is linked to congenital disorders of glycosylation, where impaired glycan maturation impacts extracellular matrix proteins, receptors, and other glycoproteins critical for cellular signaling and tissue homeostasis. As a result, TMEM165 is frequently studied in the context of Golgi biology, metal ion–dependent enzymatic processes, and glycosylation-associated disease mechanisms.
TMEM165 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TMEM165 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the TMEM165 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, TMEM165 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined TMEM165 target site.
When co-transfected with TMEM165 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the TMEM165 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.